563 Results

People

  1. Zelenetz
    Zelenetz
  2. Moskowitz
    Moskowitz
  3. Yahalom
    Yahalom
  4. Noy
    Noy
  5. De Angelis
    De Angelis
  6. Perales
    Perales
  7. Abrey
    Abrey
  8. Palomba
    Palomba
  9. Younes
    Younes
  10. Matasar
    Matasar

Groups

  1. Department of Medicine (377)
  2. Hematologic Malignancies, Division of (338)
  3. Center for Hematologic Malignancies (292)
  4. Lymphoma (192)
  5. Survivorship Research (98)
  6. Tow Center for Developmental Oncology (TCDO) (72)
  7. Bone Marrow Transplant (65)
  8. GSK Faculty (60)
  9. Epidemiology and Biostatistics (58)
  10. Adult Leukemia (53)
  1. "rituximab"
Formats
  1. Journal Article (489)
  2. Review (36)
  3. Research Letter (13)
  4. Editorial (9)
  5. Correspondence (6)
  6. Meeting Abstract (4)
  7. Book Section (2)
  8. Conference Paper (2)
  9. Guidelines (2)
Groups
  1. Department of Medicine (377)
  2. Hematologic Malignancies, Division of (338)
  3. Center for Hematologic Malignancies (292)
  4. Lymphoma (192)
  5. Survivorship Research (98)
  6. Tow Center for Developmental Oncology (TCDO) (72)

More Groups

People
  1. Andrew Zelenetz (87)
  2. Craig Moskowitz (52)
  3. Joachim Yahalom (39)
  4. Ariela Noy (35)
  5. Lisa De Angelis (32)
  6. Paul Hamlin (32)

More People

Years
  1. 2025 (21)
  2. 2024 (36)
  3. 2023 (36)
  4. 2022 (28)
  5. 2021 (14)
  6. 2020 (25)

More Years

Publications
  1. Blood (43)
  2. Leukemia and Lymphoma (38)
  3. Journal of Clinical Oncology (32)
  4. Haematologica (21)
  5. British Journal of Haematology (20)
  6. Journal of the National Comprehensive Cancer Network (16)

More Publications

Publishers
  1. Elsevier Inc. (70)
  2. American Society of Hematology (61)
  3. Taylor & Francis Group (44)
  4. Springer (42)
  5. American Society of Clinical Oncology (36)
  6. Nature Publishing Group (28)

More Publishers

Results (563)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • The impact of early discontinuation/dose modification of venetoclax on outcomes in patients with relapsed/refractory chronic lymphocytic leukemia: Post-hoc analyses from the phase III MURANO study
    Journal Article

    Mato, A. R.; Sharman, J. P.; Biondo, J. M. L.; Wu, M.; Mun, Y.; Kim, S. Y.; Humphrey, K.; Boyer, M.; Zhu, Q.; Seymour, J. F.
    Haematologica (2022)

    Fulltext@MSK | Save
  • Epstein-Barr virus-associated post-transplant lymphoproliferative disorders: Beyond chemotherapy treatment
    Review

    Shahid, S.; Prockop, S. E.
    Cancer Drug Resistance (2021)

    Fulltext@MSK | Save
  • Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib
    Journal Article

    Wang, X. V.; Hanson, C. A.; Tschumper, R. C.; Lesnick, C. E.; Braggio, E.; Paietta, E. M.; O'Brien, S.; Barrientos, J. C.; Leis, J. F.; Zhang, C. C.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Durable response to brentuximab vedotin plus cyclophosphamide, doxorubicin, and prednisone (BV-CHP) in a patient with CD30-positive PTCL arising as a post-transplant lymphoproliferative disorder (PTLD)
    Journal Article

    Hong, J.; Johnson, W. T.; Kartan, S.; Gonsalves, A. S.; Fenkel, J. M.; Gong, J. Z.; Porcu, P.
    Current Oncology (2021)

    Fulltext@MSK | Save
  • Outcomes and utilization trends of front-line autologous hematopoietic cell transplantation for mantle cell lymphoma
    Journal Article

    Riedell, P. A.; Hamadani, M.; Ahn, K. W.; Litovich, C.; Murthy, G. S. G.; Locke, F. L.; Brunstein, C. G.; Merryman, R. W.; Stiff, P. J.; Pawarode, A.; more...
    Transplantation and Cellular Therapy (2021)

    Fulltext@MSK | Save
  • Feasibility of combining the phosphatidylinositol 3-kinase inhibitor copanlisib with rituximab-based immunochemotherapy in patients with relapsed indolent B-cell lymphoma
    Journal Article

    Matasar, M. J.; Dreyling, M.; Leppä, S.; Santoro, A.; Pedersen, M.; Buvaylo, V.; Fletcher, M.; Childs, B. H.; Zinzani, P. L.
    Clinical Lymphoma, Myeloma and Leukemia (2021)

    Fulltext@MSK | Save
  • Phase I study protocol: NKTR-255 as monotherapy or combined with daratumumab or rituximab in hematologic malignancies
    Journal Article

    Shah, N.; Perales, M. A.; Turtle, C. J.; Cairo, M. S.; Cowan, A. J.; Saeed, H.; Budde, L. E.; Tan, A.; Lee, Z.; Kai, K.; more...
    Future Oncology (2021)

    Fulltext@MSK | Save
  • Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia
    Journal Article

    Herishanu, Y.; Avivi, I.; Aharon, A.; Shefer, G.; Levi, S.; Bronstein, Y.; Morales, M.; Ziv, T.; Arbel, Y. S.; Scarfò, L.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Immune-related cutaneous adverse events due to checkpoint inhibitors
    Review

    Wang, E.; Kraehenbuehl, L.; Ketosugbo, K.; Kern, J. A.; Lacouture, M. E.; Leung, D. Y. M.
    Annals of Allergy, Asthma & Immunology (2021)

    Fulltext@MSK | Save
  • T cell regeneration after immunological injury
    Review

    Velardi, E.; Tsai, J. J.; van den Brink, M. R. M.
    Nature Reviews Immunology (2021)

    Fulltext@MSK | Save